Geron Swings to Q3 Profit on $60.1M RYTELO Revenue, Cuts 2026 Opex Guidance
GERN sits 15% above its 52-week low of $0.84 on elevated volume (5.0× avg).
Summary
Geron posted Q3 2026 net income of $1.4 million on RYTELO revenue of $60.1 million, up 5% sequentially, and lowered its 2026 operating expense guidance to $220-$230 million while reiterating revenue guidance at the mid-to-high end of $220-$240 million.
Key Events · Earnings and Guidance · GERN
-
First Quarterly Profit on RYTELO Growth
Q3 2026 net income was $1.4 million, or $0.00 per share, versus a net loss of $18.4 million a year earlier, on product revenue of $60.1 million versus $47.2 million.
-
Opex Guidance Cut, Revenue Range Held
2026 total operating expenses are now guided to $220-$230 million, down from $230-$240 million, while RYTELO revenue guidance stays at the mid-to-high end of $220-$240 million.
-
Cash Rises to $339.4 Million
Cash, cash equivalents, restricted cash and marketable securities grew to $339.4 million at September 30, 2026 from $326.9 million at June 30, 2026; the company says this funds operations for the foreseeable future.
-
Gated European Launch Begins
Geron initiated a gated commercial launch in targeted EU markets, with RYTELO availability expected in Germany by end of 2026 and France in 2027, relying on third parties.
Analysis · GERN · Life Sciences
The headline is Geron's first quarterly profit: $1.4 million of net income versus an $18.4 million loss a year ago, driven by RYTELO revenue of $60.1 million and a $6.7 million drop in operating expenses. Management also trimmed the 2026 opex range to $220-$230 million while holding revenue guidance at the mid-to-high end of $220-$240 million, which means less cash burn than previously planned. With $339.4 million in cash plus U.S. RYTELO revenue, the company now expects to fund operations for the foreseeable future, removing near-term financing pressure. Against that, the October 28 discontinuation of the Phase 3 IMpactMF trial leaves the entire equity story resting on RYTELO in lower-risk MDS, and the European launch is gated and dependent on third parties, with Germany expected by year-end and France in 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GERN was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $597.5M. The 52-week trading range was $0.84 to $2.01. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.